Vivek Ramaswamy and Matt Gline swoop into Nasdaq on the wings of Jim Momtazee's SPAC with a $7B-plus Roivant debut ready to do some deals
Seven years after founding Roivant Sciences as an upstart contender in the world of biotech creation, Vivek Ramaswamy and his recently anointed CEO Matt Gline are gliding into Nasdaq on the gilded wings of a cash-heavy SPAC.
In a carefully crafted SPAC pact aimed at wedding new investors at Montes Archimedes Acquisition Corp. with a syndicate of investors coming back to re-up for the next round of company building, they’ve assembled a fresh $611 million in financing for Roivant — $411 million held in trust from the investors in MAAC with a fresh $200 million from the syndicate.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.